Director & 10% Owner Enright Invests Over $144M in Veradermics Post-IPO
MANE is trading near its 52-week low of $32 (11% above the low).
Summary
Patrick G. Enright, a Director and 10% owner of Veradermics, Inc., acquired over $144 million in company stock through open market purchases and preferred stock conversions following the company's IPO, signaling strong insider confidence.
Key Events · Ownership and Investor Activity · MANE
-
Substantial Post-IPO Investment
Patrick G. Enright, a Director and 10% owner, acquired over $144 million in Veradermics, Inc. stock, representing a significant portion of the company's market capitalization.
-
Open Market Purchases at IPO Price
The transactions include $18.275 million in direct open market purchases of common stock at the IPO price of $17.00 per share, executed on the same day the IPO closed.
-
Preferred Stock Conversions
An additional $126.7 million in common stock was acquired through the automatic conversion of Series B and Series C Convertible Preferred Stock immediately prior to the IPO closing, as detailed in the recent 424B4 and 8-K filings.
-
Strong Insider Confidence Signal
These combined transactions, particularly the discretionary open market purchases, indicate strong conviction from a key insider in the company's value and future prospects following its public debut.
Analysis · MANE · Life Sciences
This Form 4 filing reveals significant insider activity by Patrick G. Enright, a Director and 10% owner of Veradermics, Inc., immediately following the company's Initial Public Offering. The transactions, totaling over $144 million, include substantial open market purchases of common stock at the IPO price of $17.00 per share, alongside the automatic conversion of preferred stock into common stock. This considerable investment by a key insider, representing a significant portion of the company's market capitalization, signals strong confidence in Veradermics' future prospects shortly after its public market debut.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.7% of the 1013 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MANE was trading at $35.40 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $32.00 to $40.11. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.